ES2555279T3 - Neuroprotección en enfermedades desmielinizantes - Google Patents

Neuroprotección en enfermedades desmielinizantes Download PDF

Info

Publication number
ES2555279T3
ES2555279T3 ES11742896.1T ES11742896T ES2555279T3 ES 2555279 T3 ES2555279 T3 ES 2555279T3 ES 11742896 T ES11742896 T ES 11742896T ES 2555279 T3 ES2555279 T3 ES 2555279T3
Authority
ES
Spain
Prior art keywords
dmf
subject
interferon beta
administered
combination therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11742896.1T
Other languages
English (en)
Spanish (es)
Inventor
Susan Goelz
Kate Dawson
Ralf Linker
Ralf Gold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44368163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2555279(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Application granted granted Critical
Publication of ES2555279T3 publication Critical patent/ES2555279T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES11742896.1T 2010-02-12 2011-02-11 Neuroprotección en enfermedades desmielinizantes Active ES2555279T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US304325P 2001-07-10
US30432510P 2010-02-12 2010-02-12
US32148610P 2010-04-06 2010-04-06
US321486P 2010-04-06
PCT/US2011/024594 WO2011100589A1 (fr) 2010-02-12 2011-02-11 Neuroprotection dans les maladies démyélinisantes

Publications (1)

Publication Number Publication Date
ES2555279T3 true ES2555279T3 (es) 2015-12-30

Family

ID=44368163

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11742896.1T Active ES2555279T3 (es) 2010-02-12 2011-02-11 Neuroprotección en enfermedades desmielinizantes

Country Status (14)

Country Link
US (3) US20130287732A1 (fr)
EP (2) EP2533634B1 (fr)
DK (1) DK2533634T3 (fr)
ES (1) ES2555279T3 (fr)
HK (1) HK1179116A1 (fr)
HR (1) HRP20151350T1 (fr)
HU (1) HUE025878T2 (fr)
ME (1) ME02317B (fr)
PL (1) PL2533634T3 (fr)
PT (1) PT2533634E (fr)
RS (1) RS54551B1 (fr)
SI (1) SI2533634T1 (fr)
SM (1) SMT201600014B (fr)
WO (1) WO2011100589A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410805A (pt) 2003-09-09 2006-06-27 Fumapharm Ag uso de derivados do ácido fumárico para tratamento da insuficiência cardìaca e asma
DE14172398T1 (de) 2004-10-08 2015-01-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
PT2653873T (pt) 2007-02-08 2022-07-26 Biogen Ma Inc Composições e utilizações para o tratamento de esclerose múltipla
SI2139467T1 (sl) * 2007-02-08 2017-01-31 Biogen Ma Inc. Zaščita živčevja pri demielinizacijskih obolenjih
SI2564839T1 (sl) 2009-01-09 2016-09-30 Forward Pharma A/S Farmacevtska formulacija, obsegajoča enega ali več estrov fumarne kisline v erozijskem ogrodju
PL2718257T3 (pl) 2011-06-08 2018-04-30 Biogen Ma Inc. Sposób przygotowywania dimetylofumaranu krystalicznego o wysokiej czystości
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
KR102105217B1 (ko) 2012-02-07 2020-06-01 바이오젠 엠에이 인코포레이티드 다이메틸 푸마레이트를 함유하는 약학 조성물
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
EP2692343A1 (fr) 2012-08-03 2014-02-05 Forward Pharma A/S Polythérapie pour le traitement de la sclérose en plaques
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140056973A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
UA119032C2 (uk) * 2012-10-02 2019-04-25 Женеро Са Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w
US20140179779A1 (en) 2012-12-21 2014-06-26 Biogen Idec Ma Inc. Deuterium Substituted Fumarate Derivatives
EP3366668B1 (fr) 2013-03-14 2023-06-21 Alkermes Pharma Ireland Limited Promédicaments de fumarates et leur utilisation pour le traitement de diverses maladies
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート，インコーポレイティド （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用
WO2015105757A1 (fr) * 2014-01-07 2015-07-16 Biogen Ma Inc. Fumarate de diméthyle pour traiter une sclérose en plaques
EP3110793B1 (fr) 2014-02-24 2019-08-21 Alkermes Pharma Ireland Limited Sulfonamide et promédicaments de fumarates de sulfinamide et leur utilisation dans le traitement de diverses maladies
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
MA41785A (fr) 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
CA3050086A1 (fr) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Systemes de depot de glatiramere pour le traitement de formes progressives de sclerose en plaques
US11382889B2 (en) * 2018-04-19 2022-07-12 Institut D'investigació Biomèdica De Bellvitge (Idibell) NRF2 activators for the prevention and/or treatment of axonal degeneration
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
CA2343094A1 (fr) * 1998-10-16 2000-04-27 Biogen, Inc. Proteines de fusion a interferon beta et leurs utilisations
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE14172398T1 (de) 2004-10-08 2015-01-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
US20080227847A1 (en) * 2005-07-07 2008-09-18 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
US20080089861A1 (en) 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
SI2139467T1 (sl) 2007-02-08 2017-01-31 Biogen Ma Inc. Zaščita živčevja pri demielinizacijskih obolenjih
US20090104142A1 (en) * 2007-10-17 2009-04-23 Txcell Compositions for treating multiple sclerosis

Also Published As

Publication number Publication date
PL2533634T3 (pl) 2016-04-29
EP2533634A4 (fr) 2013-07-10
EP2533634A1 (fr) 2012-12-19
EP2533634B1 (fr) 2015-10-21
US20130287732A1 (en) 2013-10-31
HUE025878T2 (en) 2016-05-30
SI2533634T1 (sl) 2016-01-29
WO2011100589A1 (fr) 2011-08-18
PT2533634E (pt) 2015-12-28
RS54551B1 (en) 2016-06-30
EP2982371A1 (fr) 2016-02-10
SMT201600014B (fr) 2016-02-25
HRP20151350T1 (hr) 2016-01-01
DK2533634T3 (en) 2016-01-25
US20160250172A1 (en) 2016-09-01
HK1179116A1 (en) 2013-09-27
US20180021288A1 (en) 2018-01-25
ME02317B (me) 2016-06-20

Similar Documents

Publication Publication Date Title
ES2555279T3 (es) Neuroprotección en enfermedades desmielinizantes
ES2599227T3 (es) Neuroprotección en enfermedades desmielinizantes
US11224584B2 (en) Sleep apnea treatment
ES2859761T3 (es) Pautas posológicas para el tratamiento de enfermedad de Pompe
ES2460617T3 (es) Combinación de pilocarpina y tiamazol para tratar la enfermedad de Charcot-Marie-Tooth y los trastornos relacionados
JP2014521658A (ja) ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療
US11918551B2 (en) Methods of treating seizure disorders and Prader-Willi syndrome
AU2023204000A1 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
PT2763690E (pt) Lixisenatido para utilização no tratamento de estenose e/ou obstrução no sistema ductal pancreático
ES2655291T5 (es) Uso de cladribina para tratar neuromielitis óptica
JP2017533967A (ja) システアミン組成物を用いるハンチントン病の処置方法
JP4672257B2 (ja) エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用
US8642566B2 (en) Therapeutic approaches for treating neuroinflammatory conditions
ES2198948T3 (es) Usos de antagonistas de la substancia p para el tratamiento del sindrome de la fatiga cronica y/o de la fibromialgia.
KR20070012522A (ko) 면역조절제 화합물로의 호흡기 바이러스 감염의 치료 및예방
WO2023066330A1 (fr) Utilisation d'édaravone dans le traitement d'un trouble du spectre de l'autisme
ES2528361T3 (es) Agente antitumoral
CN113350488B (zh) 口服降糖肽ohp在制备抗神经退行性疾病药物方面的应用
US20230181498A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
US20220211647A1 (en) Compositions and methods for potentiating derivatives of 4-aminophenols
UA146735U (uk) Фармацевтичний препарат для лікування болю та запалення
CN112153967A (zh) 治疗脱髓鞘的组合物和方法
JP2013018729A (ja) アルツハイマー病治療剤の作用増強経口用剤
TW201318636A (zh) 用於治療膽道狹窄或／及阻塞之ｇｌｐ－１促效劑